Jackson, Kimberley

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 1,040

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 256

An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs

Lowe, S., Sher, E., Wishart, G., Jackson, K., Yuen, E., Brittain, C., Fong, S. C., Clarke, D. O., & Landschulz, W. H. (2017) · Drug Delivery and Translational Research

Advanced Drug Delivery SystemsAlzheimer's disease research and treatments

Cited by 10